← Back to Search

Other

SANGUINATE™ for Cerebral Ischemia

Phase 2
Waitlist Available
Led By Rajat Dhar, MD
Research Sponsored by Prolong Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days
Awards & highlights
No Placebo-Only Group

Summary

Safety and effect of SANGUINATE on patients DCI following SAH.

Eligible Conditions
  • Cerebral Ischemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Impact of SANGUINATE on brain oxygenation and blood flow assessed using Postitron Emission Tomography (PET)
Safety of study drug during and following infusion as measured by vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SANGUINATE™Experimental Treatment1 Intervention
Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SANGUINATE™
2014
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Prolong PharmaceuticalsLead Sponsor
14 Previous Clinical Trials
301 Total Patients Enrolled
Rajat Dhar, MDPrincipal InvestigatorBarnes Jewish Hospital/Washington University
2 Previous Clinical Trials
1,037 Total Patients Enrolled
Michael N Dirringer, MDStudy ChairBarnes Jewish Hospital/Washington University
~1 spots leftby Nov 2025